Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Neurol Neurosurg Psychiatry
Päätekijät: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2019
Aiheet:
Neuromuscular
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://ncbi.nlm.nih.gov/pubmed/31292200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2019-320998
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia